Literature DB >> 2187835

Bone seeking pharmaceuticals.

C L de Ligny1, W J Gelsema, T G Tji, Y M Huigen, H A Vink.   

Abstract

Mesh：

Substances：

Year:  1990        PMID： 2187835     DOI： 10.1016/0883-2897(90)90144-p

Source DB:  PubMed          Journal:  Int J Rad Appl Instrum B        ISSN： 0883-2897


× No keyword cloud information.
  6 in total

Review 1.  Selective drug delivery to bone using acidic oligopeptides.

Authors:  Junko Ishizaki; Yoshihiro Waki; Tatsuo Takahashi-Nishioka; Koichi Yokogawa; Ken-Ichi Miyamoto
Journal:  J Bone Miner Metab       Date:  2008-11-19       Impact factor: 2.626

2.  Modular 'click-in-emulsion' bone-targeted nanogels.

Authors:  Daniel A Heller; Yair Levi; Jeisa M Pelet; Joshua C Doloff; Jasmine Wallas; George W Pratt; Shan Jiang; Gaurav Sahay; Avi Schroeder; Josh E Schroeder; Yieu Chyan; Christopher Zurenko; William Querbes; Miguel Manzano; Daniel S Kohane; Robert Langer; Daniel G Anderson
Journal:  Adv Mater       Date:  2012-12-27       Impact factor: 30.849

3.  Evaluation of 99mtechnetium-radiopharmaceutical binding to blood elements using different trichloroacetic acid concentrations.

Authors:  R S Freitas; B Gutfilen; L M da Fonseca; M Bernardo-Filho
Journal:  Yale J Biol Med       Date:  1996 Nov-Dec

4.  Absorbed dose assessment of (177)Lu-zoledronate and (177)Lu-EDTMP for human based on biodistribution data in rats.

Authors:  Hassan Yousefnia; Samaneh Zolghadri; Amir Reza Jalilian
Journal:  J Med Phys       Date:  2015 Apr-Jun

5.  Production, biodistribution assessment and dosimetric evaluation of (177)Lu-TTHMP as an agent for bone pain palliation.

Authors:  Samaneh Zolghadri; Hassan Yousefnia; Amir Reza Jalilian; Mohammad Ghannadi-Maragheh
Journal:  Asia Ocean J Nucl Med Biol       Date:  2015

6.  Production and quality control 177Lu (NCA)-DOTMP as a potential agent for bone pain palliation.

Authors:  Nafise Salek; Mojtaba Shamsaei; Mohammad Ghannadi Maragheh; Simindokht Shirvani Arani; Ali Bahrami Samani
Journal:  J Appl Clin Med Phys       Date:  2016-11-08       Impact factor: 2.102
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.